KVD 001

Drug Profile

KVD 001

Alternative Names: KVD-001; Plasma kallikrein inhibitor - KalVista Pharmaceuticals

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vantia Therapeutics
  • Developer JDRF; KalVista Pharmaceuticals
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic macular oedema

Most Recent Events

  • 10 Oct 2017 KalVista and Merck agree to develop KVD 001 for Diabetic macular oedema
  • 10 Oct 2017 KalVista Pharmaceuticals and Merck plan a phase II trial in Diabetic macular oedema in 2017
  • 27 Jul 2015 KalVista Pharmaceuticals plans a phase II trial in Diabetic macular oedema in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top